Skip to content

The Actual News

Stay informed without the news wearing you out.

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

Also reported by BBC Top Stories

Summary

In a trial of 61 people with advanced pancreatic cancer, the drug daraxonrasib stopped tumours from growing in 90% of patients, while tumours shrank or became undetectable in just over 60%. After one year, 76.6% of participants were alive; researchers say longer studies are needed to learn how long the effects last and whether the drug can produce remission.

Key Facts

  • Trial participants had pancreatic cancer that had spread to other parts of the body.
  • Tumours stopped growing in 90% of the 61 participants.
  • Tumours shrank or became undetectable in just over 60% of participants.
  • Tumours were undetectable on CT scans in about 8% of participants.
  • After one year of treatment, 76.6% of participants were alive.
  • Participants were followed for an average of 18 months.
  • Daraxonrasib blocks certain KRAS mutations that can drive tumour growth.
  • Further studies are needed to assess longer-term effects and possible use in other cancers.
Read the Full Article

This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.

The week's biggest stories, one calm email every Monday.